Novo Nordisk (NVO) reports progress on multi‑billion B share buyback
Rhea-AI Filing Summary
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. As part of the programme initiated on 6 May 2026, the company bought 1,239,849 B shares for a total of DKK 369,728,627 between 6 and 13 May 2026.
This is within a broader plan to repurchase up to DKK 11,200,000,010.45 of B shares from 6 May 2026 to 1 February 2027, and up to DKK 15 billion over 12 months beginning 4 February 2026. As of 13 May 2026, Novo Nordisk has repurchased 15,999,028 B shares for DKK 4,169,728,617 at an average price of DKK 260.62 per share.
After these transactions, Novo Nordisk holds 33,184,329 B shares of DKK 0.10 as treasury shares, equal to 0.7% of its total share capital of 4,465,000,000 A and B shares.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Safe Harbour Rules regulatory
Regulation No 596/2014 regulatory
Commission Delegated Regulation (EU) 2016/1052 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What has Novo Nordisk repurchased since the broader programme began on 4 February 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 18, 2026
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé 1
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark,18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement of the programme, the following transactions have been made:
Number of B shares |
Average purchase price |
Transaction value, DKK | |
| 6 May 2026 | 199,849 | 300.66 | 60,086,659 |
| 7 May 2026 | 200,000 | 294.37 | 58,873,625 |
| 8 May 2026 | 210,000 | 290.45 | 60,993,987 |
| 11 May 2026 | 210,000 | 300.49 | 63,103,075 |
| 12 May 2026 | 210,000 | 300.81 | 63,169,735 |
| 13 May 2026 | 210,000 | 302.39 | 63,501,546 |
| Accumulated under the programme | 1,239,849 | 369,728,627 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 204,498 shares in the period from 6 May 2026 to 13 May 2026. The shares in these transactions were not part of the Safe Habour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 33,184,329 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 13 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 15,999,028 B shares at an average share price of DKK 260.62 per B share equal to a transaction value of DKK 4,169,728,617.
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | Liz Skrbkova (US) | ||
| Ambre James-Brown | +1 609 917 0632 | ||
| +45 3079 9289 | lzsk@novonordisk.com | ||
| globalmedia@novonordisk.com | |||
| Investors: | |||
| Michael Novod | Jacob Martin Wiborg Rode | ||
| +45 3075 6050 | +45 3075 5956 | ||
| nvno@novonordisk.com | jrde@novonordisk.com | ||
| Max Ung | Sina Meyer | ||
| +45 3077 6414 | +45 3079 6656 | ||
| mxun@novonordisk.com | azey@novonordisk.com | ||
| Alex Bruce | Christoffer Sho Togo Tullin | ||
| +45 34 44 26 13 | +45 3079 1471 | ||
| axeu@novonordisk.com | cftu@novonordisk.com | ||
| Frederik Taylor Pitter | Mads Berner Bruun | ||
| +1 609 613 0568 | +45 3075 2936 | ||
| fptr@novonordisk.com | mbbz@novonordisk.com | ||
Novo Nordisk A/S Investor Relations | Novo Allé 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 | www.novonordisk.com |
| Company announcement No 32 / 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: May 18, 2026 |
NOVO NORDISK A/S
Maziar Mike Doustdar Chief Executive Officer |